The Effects of Therapy With Teriparatide on Vascular Compliance and Osteoprotegerin/RANKL

Withdrawn before enrolling · Not applicable

Conditions studied: Osteoporosis

In brief

The purpose of this study is to determine what effect teriparatide will have on vascular (blood vessel) compliance and osteoprotegerin (bone fluid)and RANKL levels (bone cells).

Key facts

Study ID

NCT00347737

Run by

Leland Graves III, MD

People needed

0

Starts

2006-06-01

Expected to finish

2008-05-01

Last updated by the study team

2013-01-16

Who can join

Age: 40 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Postmenopausal women and men over the age of 40 who are starting therapy with teriparatide

You may not qualify if…

• Patients with diabetes mellitus
• current smokers
• patients with a history of organ transplantation
• Patients currently of previously on glucocorticoid therapy within the past year
• Patients with serum creatinine above 1.5 mg/dl, patients with uncontrolled hypertension (BP 140/90 or greater)
• Patients ineligible for teriparatide therapy: History of metabolic bone disease other than osteoporosis
• History of radiation therapy
• Patients pregnant or nursing
• History of bone metastasis or skeletal malignancies
• History of hypercalcemia

Where it is running

• University of Kansas Medical Center — Kansas City, Kansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.